bmiMD Review: The $99 Semaglutide Costs $129 Month to Month

Between $99 and $129 a month for compounded semaglutide, and between $139 and $179 for compounded tirzepatide, depending entirely on how far ahead you pay. Read off bmiMD's own checkout on August 9, 2026: semaglutide is $1,188 for twelve months, $654 for six, $357 for three, and $129 for one; tirzepatide is $1,668 for twelve, $894 for six, $477 for three, and $179 for one. The advertised figures are the twelve-month plans divided out. If you want one month with no commitment, the numbers are $129 and $179.

No, and bmiMD is one of the few sellers in this category whose own checkout proves it rather than promising it. Add the monthly semaglutide plan and the order summary reads "GLP-1 Monthly Treatment Plan $129 / month", "Next renewal total $129.00", "First renewal: September 9, 2026". Same figure, same product, no step-up. The one exception is a referral lander at /compounded-glp-1-semaglutide-nift/, which offers a $30-off first month and labels it "$99 /1st mo" against a $129 total — honestly marked, but a different offer from the one on the storefront.

Twelve payments of $129 is $1,548 for semaglutide, and twelve of $179 is $2,148 for tirzepatide. Pay for the year up front instead and it is $1,188 and $1,668 — so committing saves $360 and $480. That is a smaller premium for flexibility than most of this category charges, which makes the month-to-month plan a genuinely reasonable place to start. The catch is on the other side: bmiMD does not refund partially used subscription periods, so if you take the twelve-month price and stop in month three, the remaining nine months are not coming back.

After a clinician has said yes, which is the right way round and not how this category usually works. Its refund policy: "Once you've submitted your order, we'll authorize your card. Shortly after, you'll receive a HIPAA-compliant medical intake form to complete. Once your eligibility is confirmed by the licensed provider, we'll process the authorized payment. If it turns out you're not eligible for the program, we'll release the authorization hold, and you won't incur any charges." So a declined application costs you nothing. What does cost is changing your mind after approval — cancel between the provider signing off and the pharmacy processing, and a non-refundable $50 fee applies.

No. "Same price at every dose" sits on every product page, and it survives the checkout: the plans are named by compound and duration only — "GLP-1 12 Month Treatment Plan", "Compounded GLP/GIP Monthly Plan" — with no dose variant to select and no dose surcharge in the order summary. For a drug you titrate upward over months, that is the difference between a quote and a budget. bmiMD also sells compounded semaglutide and tirzepatide microdose products, and prices them identically rather than at a premium.

bmiMD names it, which is worth something. Its terms give the fulfilment pharmacy as Precision Compounding Pharmacy, 2657 Merrick Road, Bellmore, NY 11710, with a phone number, and say the company "sources its prescription medication from licensed 503a compounding pharmacies" chosen by the state you live in. Two caveats. The terms say "the compounding pharmacies listed below" and then list one, so the state-by-state network is asserted rather than shown. And the same terms tell you that you may fill the prescription at any pharmacy of your choice instead — a right most telehealth sellers in this category do not extend.

Almost certainly, but the evidence is weaker than it looks. Its homepage FAQ says bmiMD "connects patients to licensed healthcare professionals in all 50 states", and nothing in the funnel contradicts that. What is missing is any point at which the claim is tested: the eligibility quiz never asks where you live, and the state dropdown at checkout is WooCommerce's stock US list — the 50 states, D.C. and three Armed Forces entries — which every WooCommerce store on the internet ships with. No state is refused anywhere we could reach without submitting an order, so no exclusion is named here.

The prices are, with one exception we could reproduce. Every tier on the semaglutide and tirzepatide product pages matches its checkout line exactly. The exception is the tirzepatide microdose page, which prints its three-month plan as "$159/month … Total Price: $357" — but $159 × 3 is $477, and $357 is the three-month total from the semaglutide page. The checkout charges $477. It is a copy error rather than a trap, and it is the exact failure this site's method exists to catch: a price that belongs to the other molecule, sitting under the right one.

Treat them as decoration. The "SUMMER CLOSEOUT" strip runs across every page and its countdown renders the literal words "Ends soon" where a time should be. Behind a "How the price freeze works" panel, present in the markup of every page, sits the line "Join before Aug 4 and today's rate becomes your rate" alongside "when prices go up on Aug 4". On August 9, 2026 that date was five days gone and every price on the site was unchanged. bmiMD's own safety page reserves the right to "adjust pricing from time to time in accordance with supply and market conditions", which is the honest version of the same statement.

No. FDA's live warning-letter index was queried on August 9, 2026 for "bmimd", "bmi md", for the corporate name "medccm", and for the pharmacy it names. bmiMD and Medccm returned zero. The spaced query "bmi md" returned two rows, but their company columns read Eli Lilly and Company and Nana Barseghian, M.D. — the phrase matched inside letter bodies, not a company name, and neither is this business. The pharmacy query returned one row for a different pharmacy entirely, Stokes Healthcare Inc. dba Epicur Pharma. A query for "skinnyrx" in the same pass returned that company's February 2026 letter, which is what makes the zeros meaningful rather than a sign of a broken search.